SCHEMBL4895950

SCHEMBL4895950

CCN(c1ccc2oc(-c3ccccc3)nc2c1)S(=O)(=O)c1ccc(C(C)C)c(C(=O)O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.48
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HDAC6 Q9UBN7 2/20 0.46
CYP1A2 P05177 1/20 0.46
AHR P35869 1/20 0.46
UTRN P46939 1/20 0.46
PTPN22 Q9Y2R2 6/20 0.44
PTPN1 P18031 5/20 0.44
PTPN12 Q05209 2/20 0.44
BCL2L1 Q07817 4/20 0.44
MCL1 Q07820 4/20 0.44
PTPN5 P54829 3/20 0.44
PTPN2 P17706 2/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
CASP3 P42574 2/20 0.42
SENP7 Q9BQF6 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4906129 0.93 PTPN1 (0.46) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4904660 0.89 LMNA (0.49) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4903801 0.89 LMNA (0.49) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4909040 0.84 LMNA (0.44) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4897744 0.83 PTPN1 (0.49) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4905178 0.83 PTPN1 (0.47) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4905884 0.81 LMNA (0.46) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4902530 0.81 LMNA (0.47) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4905727 0.80 HPGD (0.47) LMNAHPGDALDH1A1ALOX15HSD17B10
SCHEMBL4912012 0.79 PTPN1 (0.46) HPGDALDH1A1HSD17B10HDAC6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765796-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Inc. (US) 2007-03-28 EP claimed
WO-2006003495-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2006-01-12 WO claimed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US claimed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885HPGD 724/4885ALDH1A1 2956/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885HPGD 724/4885ALDH1A1 2956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.